| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.4 | 0.01 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |